HK Stock Market Move | VISEN PHARMA-B(02561) rose more than 7% and the company's core product Longpeak growth hormone is expected to be approved by 2025.

Visen Pharma-B (02561) rose by over 7%, reaching a 7.6% increase to HK$43.9 as of the time of writing, with a turnover of HK$1.4598 million. According to the prospectus, Visen Pharma is an innovative biopharmaceutical company specializing in the field of endocrine-related therapies. Its core product line focuses on endocrinology, particularly growth and developmental disorders. Its core product, Long-Acting Growth Hormone (LAGH), the first long-acting growth hormone simultaneously approved by the FDA and EMA for the treatment of Pediatric Growth Hormone Deficiency (PGHD), is the only long-acting growth hormone that has been proven in clinical trials to be more effective than daily growth hormone formulations. Notably, Visen Pharma has steadily progressed the commercialization process of three drugs in recent years. The core product, LAGH, is expected to be approved by 2025, with the market application accepted by the Chinese FDA in March 2024. The other two high-quality pipeline products, Navapeptide and Paropeptide, have also reached their primary clinical endpoints in domestic clinical trials.